George Budwell

George Budwell

TMFGBudwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles














Better Buy: AbbVie vs. Eli Lilly

AbbVie and Eli Lilly have both stumbled this year. Which of these top pharma stocks is better positioned for a rebound?